Articles From: Synta to Host Conference Call and Webcast of Second Quarter 2014 Financial Results on August 6, 2014 to Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough (Pertussis) at Gordon Research Conference


Synta Pharmaceuticals Corp.
Sign-up for Synta to Host Conference Call and Webcast of Second Quarter 2014 Financial Results on August 6, 2014 investment picks
ADVISORY, Sept.
Sign-up for Syntel (NASDAQ: SYNT) to Ring The NASDAQ Stock Market Closing Bell investment picks
TROY, Mich., Sept.
Sign-up for Syntel Appoints Christopher Mason to Lead North American Sales Efforts investment picks
2014/7/16
TROY, Mich., July 16, 2014 (GLOBE NEWSWIRE) -- Syntel, Inc., a global provider of digital transformation, information technology and knowledge process services to Global 2000 companies, today announced that two new members were elected to the Company's Board of Directors on July 13, 2014.
Sign-up for Syntel Elects New Members to Board of Directors investment picks
Highlights: Q2 revenue of $228.3M, up 13% from year-ago quarter, 4% sequentially Q2 EPS of $1.41 per diluted share, up 24% from year-ago quarter, 2% sequentially Q2 cash & short term investments of $769.8M Global Headcount of 24,122 on June 30, 2014, up 5% versus prior year TROY, Mich., July 17, 2014 (GLOBE NEWSWIRE) -- Syntel, Inc. (Nasdaq:SYNT) , a global provider of digital transformation, information technology and knowledge process services to Global 2000 companies, today announced financial results for the second quarter, ended June 30, 2014.
Sign-up for Syntel Reports Second Quarter 2014 Financial Results investment picks
TROY, Mich., June 24, 2014 (GLOBE NEWSWIRE) -- Syntel, Inc. (Nasdaq:SYNT) , a global provider of digital transformation, information technology and knowledge process services to Global 2000 companies, today announced it is a presenting sponsor for the Enactus India National Competition to be held at the Taj Lands' End Hotel in Mumbai, India on July 1 and 2, 2014.
Sign-up for Syntel Sponsors Enactus India Sustainable Entrepreneurship Competition investment picks
2014/7/11
TROY, Mich., July 11, 2014 (GLOBE NEWSWIRE) -- Syntel, Inc., a global provider of digital transformation, information technology and knowledge process services to Global 2000 companies, will announce results for the Second Quarter 2014, before the market opens on Thursday, July 17, 2014 Syntel management will conduct a conference call at 10:00 a.m. (EDT) to discuss financial and operating performance for the quarter.
Sign-up for Syntel to Announce Second Quarter 2014 Results on Thursday, July 17, 2014 investment picks
TROY, Mich., July 28, 2014 (GLOBE NEWSWIRE) -- Syntel (Nasdaq:SYNT) , a global provider of digital transformation, information technology and knowledge process services to Global 2000 companies, today announced that the Company will present at the following upcoming investor conference: Needham Interconnect Conference Date: Wednesday, August 6, 2014 Presentation: 12:15PM (Eastern) Location: New York, NY Presenter: Zaineb Bokhari, VP Finance Live webcast available on Syntel's website at http://investor.syntelinc.com About Syntel Syntel (Nasdaq:SYNT) is a global provider of digital transformation, information technology and knowledge process services to Global 2000 companies.
Sign-up for Syntel to Present at Investor Conference investment picks
TROY, Mich., Aug.
Sign-up for Syntel to Present at Investor Conference investment picks
HOUSTON, July 9, 2014 (GLOBE NEWSWIRE) -- Synthesis Energy Systems, Inc. (SES) (Nasdaq:SYMX) today announced that Charles M.
Sign-up for Synthesis Energy Systems Appoints Charles M. Brown to Board of Directors investment picks
HOUSTON, Aug.
Sign-up for Synthesis Energy Systems Strengthens Operations Leadership investment picks
2014/8/28
-- Fujifilm's pAVEway™ Platform Demonstrated >25-fold Improvement in SYN-004 Expression Titers --
Sign-up for Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile investment picks
-- Two of Company's Anti-Infective Programs to be Presented at Highly Regarded Scientific Conference: Pertussis and C.
Sign-up for Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC investment picks
-- SYN-005 Neutralizing Antibody Combination Protects Against Pertussis in Murine and Non-Human Primate Models --
Sign-up for Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program investment picks
2014/8/5
-- Executed Agreement with Evonik for Formulation Development, Analytical Services andClinical Drug Manufacturing -- --
Sign-up for Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile investment picks
-- Company Expects to File IND to Support Clinical Trials in Mid-2015 --
Sign-up for Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis) investment picks
2014/8/14
-- Expanded Data from Phase II MS Trial to be Released Next Month; Plans on Course to Advance C.
Sign-up for Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights investment picks
-- Keynote Speaker: Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center; Chairman, Synthetic Biologics' C-IBS Clinical Advisory Board --
Sign-up for Synthetic Biologics to Host Irritable Bowel Syndrome (IBS) Investor Day investment picks
2014/9/11
-- Conference Call Scheduled for Friday, September 12, 2014, at 9:15 a.m. EDT --
Sign-up for Synthetic Biologics to Host Phase II Trimesta™ for Multiple Sclerosis Conference Call investment picks
-- Company Completes Final Preclinical Toxicology Study and Prepares to File Investigational New Drug (IND) in 2H 2014 --
Sign-up for Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections investment picks
2014/8/7
-- Conference Call Scheduled for Thursday, August 14, 2014, at 8:30 am EDT --
Sign-up for Synthetic Biologics to Report Second Quarter 2014 Financial Results investment picks
-- Keynote Speaker: Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center; Chairman, Synthetic Biologics' C-IBS Clinical Advisory Board --
Sign-up for Synthetic Biologics to Webcast September 16, 2014 Irritable Bowel Syndrome (IBS) Investor Day investment picks
2014/7/29
ROCKVILLE, Md.
Sign-up for Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity investment picks
2014/7/21
Company's License from The University of Texas at Austin Covers Development of SYN-005 in Collaboration with Intrexon Corporation ROCKVILLE, Md.
Sign-up for Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough (Pertussis) at Gordon Research Conference investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Synta to Host Conference Call and Webcast of Second Quarter 2014 Financial Results on August 6, 2014 to Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough (Pertussis) at Gordon Research Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices